Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025Right-sizing commercial efforts to ...

The "Febrile Neutropenia - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.The clinical trials report provides an overview of the Febrile Neutropenia ...

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...

Shares of rare disease drug developer X4 Pharmaceuticals took a battering after it said it will restructure its workforce and ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its ...

Nearly one year after winning an FDA drug approval to treat an ultra-rare disease, X4 Pharmaceuticals is making layoffs that ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

X4 Pharmaceuticals (XFOR) announced a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

X4 Pharmaceuticals, Inc.’s XFOR share price has dipped by 10.83%, which has investors questioning if this is right time to ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...